| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NBT1196-1516 |
| P953 | full work available at URL | http://www.nature.com/articles/nbt1196-1516 |
| http://www.nature.com/articles/nbt1196-1516.pdf | ||
| P698 | PubMed publication ID | 9634812 |
| P2093 | author name string | J. Drews | |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug design | Q2991682 |
| P304 | page(s) | 1516-1518 | |
| P577 | publication date | 1996-11-01 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | Genomic sciences and the medicine of tomorrow | |
| P478 | volume | 14 |
| Q39026969 | A comprehensive map of molecular drug targets. |
| Q37194629 | A constitutively active GPCR governs morphogenic transitions in Cryptococcus neoformans |
| Q33215351 | Affinity ligand selection from a library of small molecules: assay development, screening, and application |
| Q53231809 | Alzheimer's disease. A firm base for drug development |
| Q34021785 | Application of a Double Aza-Michael Reaction in a ‘Click, Click, Cy-Click’ Strategy: From Bench to Flow |
| Q36950568 | Assessment of constitutive activity of a G protein-coupled receptor, CPR2, in Cryptococcus neoformans by heterologous and homologous methods |
| Q74560493 | Biotechnology's metamorphosis into a drug discovery industry |
| Q73576593 | Chemical ligands, genomics and drug discovery |
| Q28260664 | Chemogenomics: an emerging strategy for rapid target and drug discovery |
| Q46916180 | Conserved network properties of helical membrane protein structures and its implication for improving membrane protein homology modeling at the twilight zone |
| Q33859300 | Discovering novel chemotherapeutic drugs for the third millennium |
| Q36039820 | Disease-specific target selection: a critical first step down the right road |
| Q38089909 | Drug target central |
| Q28475443 | Drug-induced regulation of target expression |
| Q30660926 | Drug-like properties and the causes of poor solubility and poor permeability |
| Q33294520 | Efficacy of different protein descriptors in predicting protein functional families. |
| Q26741869 | Emerging role of bioinformatics tools and software in evolution of clinical research |
| Q47893147 | Evidence-Based Precision Oncology with the Cancer Targetome. |
| Q34660378 | Exploring a role for heteromerization in GPCR signalling specificity |
| Q28679239 | GPCRDB: an information system for G protein-coupled receptors |
| Q24813500 | GRIFFIN: a system for predicting GPCR-G-protein coupling selectivity using a support vector machine and a hidden Markov model |
| Q28547097 | Gene Ontology and KEGG Pathway Enrichment Analysis of a Drug Target-Based Classification System |
| Q35236771 | Genetic variation and pharmacogenomics: concepts, facts, and challenges |
| Q29615876 | Global mapping of pharmacological space |
| Q28276660 | How many drug targets are there? |
| Q36213270 | How many genomics targets can a portfolio afford? |
| Q41905622 | Identifying druggable targets by protein microenvironments matching: application to transcription factors |
| Q74560507 | In silico drug discovery: Tools for bridging the NCE gap |
| Q33926428 | In vitro display technologies - new tools for drug discovery |
| Q53130900 | Interaction of Herbal Compounds with Biological Targets: A Case Study with Berberine |
| Q73204350 | Keeping pace with genomics through combinatorial chemistry |
| Q86397538 | Lead generation: reality check on commonly held views |
| Q40787903 | Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes |
| Q37711794 | Lymphatic deletion of calcitonin receptor-like receptor exacerbates intestinal inflammation |
| Q35202868 | Medicinal chemistry of target family-directed masterkeys |
| Q47223367 | Meta-basic estimates the size of druggable human genome |
| Q38938718 | Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma |
| Q37590929 | Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs |
| Q35187767 | Model systems in drug discovery: chemical genetics meets genomics |
| Q36287437 | Multi-algorithm and multi-model based drug target prediction and web server |
| Q55506993 | Neurotransmitters and Their Receptors – 2003. |
| Q30874393 | Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. |
| Q32033247 | Peptide and peptidomimetic libraries. Molecular diversity and drug design |
| Q73798847 | Pharmacogenetics and drug metabolism |
| Q35936197 | Phenotypic screens as a renewed approach for drug discovery |
| Q34620185 | Prioritizing the proteome: identifying pharmaceutically relevant targets |
| Q43450643 | Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank |
| Q34092071 | Proteomics: new perspectives, new biomedical opportunities |
| Q33586063 | Proteomics: quantitative and physical mapping of cellular proteins |
| Q34666570 | Rapid design of denaturing gradient-based two-dimensional electrophoretic gene mutational scanning tests |
| Q28751421 | Reagent based DOS: a "Click, Click, Cyclize" strategy to probe chemical space |
| Q47753454 | Receptor Reporter Systems |
| Q34576618 | Receptor heterodimerization: a new level of cross-talk |
| Q57660243 | Risks of Future Drugs |
| Q74131200 | Serial analysis of gene expression: from gene discovery to target identification |
| Q43966763 | Synthesis of a novel fluorescent probe for estrogen receptor |
| Q34152440 | Synthesis of a unique isoindoline/tetrahydroisoquinoline-based tricyclic sultam library utilizing a Heck-aza-Michael strategy |
| Q37953017 | Systems biology impact on antiepileptic drug discovery |
| Q42015300 | Target-based whole-cell screening by ¹H NMR spectroscopy |
| Q41268689 | The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans‐inhibition |
| Q29547361 | The druggable genome |
| Q74471514 | The emerging role of the genomics revolution in agricultural biotechnology |
| Q80833899 | The impact of systems approaches on biological problems in drug discovery |
| Q32062858 | The mathematics of SELEX against complex targets |
| Q40702411 | Transgenic knockouts as part of high-throughput, evidence-based target selection and validation strategies |
| Q34205159 | Trends in the exploitation of novel drug targets |
| Q73359251 | Validation of genomics-derived drug targets using yeast |
| Q34172972 | What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? |
Search more.